Nektar Therapeutics (NASDAQ:NKTR) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $23.489 million which beat the analyst consensus estimate of $17.545 million by 33.88 percent. This is a 14.59 percent increase over sales of $20.499 million the same period last year.
Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.